Post-line Treatment With Teniposide for c-Myc-driven Extensive-stage Small Cell Lung Cancer

Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-75
SponsorShanghai Pulmonary Hospital, Shanghai, China

About this trial

The study is being conducted to investigate the efficacy and safety of teniposide in patients with extensive-stage small cell lung cancer who have failed standard treatment and with high expression of the c-Myc-driven FBXW2/MYC gene. Based on the results, the study will explore the correlation between the expression of FBXW2/MYC and the efficacy of teniposide.

Eligibility criteria

Qualifiers

extensive stage small cell lung cancer

Progression after receiving at least one chemotherapy drug treatment in the past;

ECOG score 0-1

c-Myc-driven

Disqualifiers

No measurable lesions

Other severe and persistent diseases or organ system dysfunction;

Women planning pregnancy or men planning family planning;

Women who are pregnant or breastfeeding;

Trial design

Treatments tested in this trial

  • Teniposide administration

Treatment groups

15 Participants
are divided into 1 treatment group

Sponsors and collaborators

Shanghai Pulmonary Hospital, Shanghai, China

Lead sponsor

CHINA RESOURCES DOUBLE-CRANE PHARMACEUTICAL CO.,LTD

Collaborator